Neuronetics Settles Litigation Against BrainsWay
10 janv. 2023 08h00 HE
|
Neuronetics
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
09 janv. 2023 08h30 HE
|
Neuronetics
MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors
29 déc. 2022 16h29 HE
|
Neuronetics
MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 déc. 2022 16h30 HE
|
Neuronetics
MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
05 déc. 2022 08h32 HE
|
Neuronetics
MALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
21 nov. 2022 16h30 HE
|
Neuronetics
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
14 nov. 2022 08h33 HE
|
Neuronetics
MALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 nov. 2022 20h04 HE
|
Neuronetics
MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Third Quarter 2022 Financial and Operating Results
08 nov. 2022 07h30 HE
|
Neuronetics
MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
31 oct. 2022 08h31 HE
|
Neuronetics
MALVERN, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...